JD Health AI Products Debut at 2026 World AI Conference, 'Dawei' User Base Surges Over 4x

Summary

At WAIC 2026, JD Health showcased its AI doctor 'Dawei' and professional tool 'Jingdong Zhiyi.' The company reported that 'Dawei's' user base in the first three months of 2026 has already exceeded the total for the entire year of 2025, with a 98% satisfaction rate and over 4x year-over-year growth during the 618 shopping festival Zhitong.

Impact Analysis

JD Health is signaling that AI in healthcare has officially moved from 'experimental' to 'essential.' The standout isn't just their presence at WAIC 2026, but the sheer velocity of adoption: the AI doctor 'Dawei' saw Q1 2026 user numbers surpass the entirety of 2025 Zhitong. This isn't a pilot; it's an inflection point.

The interesting part is the dual-track strategy. By deploying 'Dawei' for consumers and 'Jingdong Zhiyi' for professional evidence-based medicine, they are tackling both sides of the efficiency equation . A 98% satisfaction rate alongside a 4x surge in users during the 618 festival suggests they’ve solved the 'trust gap' that usually plagues medical AI Zhitong.

I’d read this as a massive margin expansion play. In a market where WAIC is shifting focus from AI 'performing' to AI 'working' 科创板日报, JD Health is proving it can automate high-volume interactions without degrading quality. If this trajectory holds, their cost-to-serve will decouple from revenue growth far faster than traditional telehealth competitors. This is a scale story hidden in a tech demo.